Long-term survival rates in the present study compared with those reported with immunochemotherapy regimens
| Reference . | Study . | ClinicalTrials.gov identifier . | Regimen . | N . | 10-y OS (95% CI), % . |
|---|---|---|---|---|---|
| Present study | SAKK 35/03 | NCT00227695 | 4× R weekly + short R maintenance | 82 | 77.9 (66.3-85.9) |
| 4× R weekly + long R maintenance | 83 | 79.0 (67.9-86.7) | |||
| Morschhauser et al, 201321 | FIT | NCT00185393 | Chemotherapy ± R* | 202 | 81 (NR) at 8 y |
| Chemotherapy ± R* +90Y-ibritumomab | 207 | 84 (NR) at 8 y | |||
| Bachy et al, 201318 | FL2000 | NCT00136552 | CHVP + interferon | 183 | 69.8 (63.1-76.6) at 8 y |
| R-CHVP + interferon | 175 | 78.6 (72.5-84.7) at 8 y | |||
| Rummel et al, 201723 | StiL NHL1 | NCT00991211 | R-bendamustine | 261 | 71 (NR) |
| R-CHOP | 253 | 66 (NR) | |||
| Nastoupil et al, 201722 | MDACC | NCT00577993 | FND, followed by R and IFN | 78 | 76 (67-86) |
| R-FND followed by IFN | 80 | 73 (64-84) | |||
| Luminari et al, 201820 | FOLL05 | NCT00774826 | R-CVP | 178 | 85 (77-91) at 8 y |
| R-CHOP | 178 | 83 (75-89) at 8 y | |||
| R-FM | 178 | 79 (71-85) at 8 y | |||
| Shadman et al, 201824 | SWOG-S0016 | NCT00006721 | R-CHOP | 267 | 81 (75.9-85.4) |
| CHOP + 131I-tositumomab | 264 | 75 (69.3-80.2) | |||
| Bachy et al, 201919 | PRIMA | NCT00140582 | R-CHOP/R-CVP/R-FCM | 513 | 79.9 (NR) |
| R-CHOP/R-CVP/R-FCM + R maintenance | 505 | 80.1 (NR) |
| Reference . | Study . | ClinicalTrials.gov identifier . | Regimen . | N . | 10-y OS (95% CI), % . |
|---|---|---|---|---|---|
| Present study | SAKK 35/03 | NCT00227695 | 4× R weekly + short R maintenance | 82 | 77.9 (66.3-85.9) |
| 4× R weekly + long R maintenance | 83 | 79.0 (67.9-86.7) | |||
| Morschhauser et al, 201321 | FIT | NCT00185393 | Chemotherapy ± R* | 202 | 81 (NR) at 8 y |
| Chemotherapy ± R* +90Y-ibritumomab | 207 | 84 (NR) at 8 y | |||
| Bachy et al, 201318 | FL2000 | NCT00136552 | CHVP + interferon | 183 | 69.8 (63.1-76.6) at 8 y |
| R-CHVP + interferon | 175 | 78.6 (72.5-84.7) at 8 y | |||
| Rummel et al, 201723 | StiL NHL1 | NCT00991211 | R-bendamustine | 261 | 71 (NR) |
| R-CHOP | 253 | 66 (NR) | |||
| Nastoupil et al, 201722 | MDACC | NCT00577993 | FND, followed by R and IFN | 78 | 76 (67-86) |
| R-FND followed by IFN | 80 | 73 (64-84) | |||
| Luminari et al, 201820 | FOLL05 | NCT00774826 | R-CVP | 178 | 85 (77-91) at 8 y |
| R-CHOP | 178 | 83 (75-89) at 8 y | |||
| R-FM | 178 | 79 (71-85) at 8 y | |||
| Shadman et al, 201824 | SWOG-S0016 | NCT00006721 | R-CHOP | 267 | 81 (75.9-85.4) |
| CHOP + 131I-tositumomab | 264 | 75 (69.3-80.2) | |||
| Bachy et al, 201919 | PRIMA | NCT00140582 | R-CHOP/R-CVP/R-FCM | 513 | 79.9 (NR) |
| R-CHOP/R-CVP/R-FCM + R maintenance | 505 | 80.1 (NR) |
CHOP, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine, and prednisolone; CHVP, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), etoposide, and prednisolone; CVP, cyclophosphamide, vincristine, and prednisone; IFN, interferon; NR, not reported; R, rituximab; R-FCM, rituximab, fludarabine, cyclophosphamide, and mitoxantrone; R-FM, rituximab, fludarabine, and mitoxantrone; R-FND, rituximab, fludarabine, mitoxantrone, and dexamethasone; ±, with or without.
First-line therapy with chlorambucil, CVP, CHOP, CHOP-like, fludarabine combinations, with or without rituximab.